Tagged with UK

Ukraine Tatyana Pechaeva, Managing Director of the Lekhim Group, one of Ukraine’s top ten domestic pharmaceutical companies, shares the main principles of her strategy which have enabled Lekhim to display high growth rates over recent years despite the country’s unstable economy. The Lekhim group of companies was one of the pioneers…

Ukraine Alexandra Sologub, managing director of Liktravy, the leading herbal pharmaceutical company in Ukraine, describes the skills she has brought over from her experience working for Darnitsa and TEVA and goes into depth about the challenges and opportunities she identifies for the company as she endeavors to gain contacts with the…

Ukraine Victoria Tarabanova, country manager of the Ukrainian office of Wörwag Pharma, a company dedicated to treating diabetic comorbidities such as neuropathic, cardiovascular and neurological diseases, provides insights into the company’s remarkable efforts to enhance Ukraine’s health ecosystem and its enduring commitment to Ukrainian patients and physicians – even during the…

Ukraine Dr. Natalya Gudz, head of the State Service of Ukraine on Medicines and Drugs Control (SMDC), provides her vision for the development of Ukraine’s key regulatory authority and the win-win relationship she wants to bolster between the pharmaceutical and healthcare companies operating in Ukraine and SMDC’s international counterparts. You took…

Ukraine Denis Shevchenko, founder of the NGO and charitable foundation PharmVarta, provides insights into the main initiatives of this independent, non-profit organization that has freely supplied Ukrainian patients with more than 1.5 million packs over the past 18 months, while he also highlights some critical regulatory updates that could further improve…

Ukraine Alexander Markus, chairman of the board of the recently set up German-Ukrainian Chamber of Industry and Commerce, provides insights into the new dynamics driving the growth of Ukraine’s foreign trade as well as the chamber’s strategic priorities to further enhance the thriving bilateral business relationship between the two countries. Leveraging…

Ukraine Dr. Volodymyr Redko, executive director of Ukraine’s Association of Pharmaceutical Research and Development (APRaD), which gathers together 15 international R&D-driven companies, provides insights into the perspective of international innovators vis-à-vis the numerous regulatory and structural reforms that are set to transform the country’s health system, while highlighting the importance that…

Ireland The UK’s decision to leave the EU in Summer 2016 sent shockwaves throughout Europe and left neighbouring countries struggling to interpret what ‘Brexit’ means for them. Ireland, as the UK’s closest neighbour both culturally and geographically, could stand to benefit from the decision in the medium- to long-term, especially in…

Pharma Leading in some areas, lagging in others, the Italian healthcare logistics sector is on the brink of change according to UPS Healthcare’s managing director for Italy, Jaap Heukers.  Each country has slightly different interpretations of certain regulations and compliance, given their unique regulatory development path. Coming from a global international…

Pharma The Director of the State Institute for Drug Control in the Czech Republic highlights the Czech pharmaceutical industry as emancipated and points out their tremendous contribution to employment, export balance, the economy at large and to the patients. You assumed the position as interim director of the State Institute for…

Pharma The managing director of CSL Behring Hungary, Attila Lukács, discusses the company’s recent establishment in Hungary, the strategic benefits the country offers, as well as his experience starting an affiliate from scratch. He also shares his thoughts on the recent expansion of CSL Plasma in Hungary and his vision for…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your speech today, you mentioned that the concept of patient-centrality has not changed, but that expectations around it have; could you…